Axitinib: Optimizando el tratamiento de segunda línea del cáncer renal - page 17

AXIS:

PFS with Axitinib by duration of prior Sunitinib

therapy

Rini et al ASCO 2014

Sunitinib Primary Refractaroy patients could also benefit from 2L Axitinib

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,7,8,9,10,11,12,13,14,15,16 18,19,20,21,22,23,24,25,26,27,...44